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Aims and objectives: 
 
 
1. To determine the prevalence of metastasis to the facial node in oral 
carcinoma. 
2. To determine whether a palpable facial lymph node correlates with 
metastasis. 
3. To determine whether the presence of metastasis in the facial node 
correlates with the outcome in terms of local recurrence and long term 
survival. 
4. To determine whether routine facial node dissection is indicated in all 
patients undergoing a neck dissection for oral malignancies. 
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Introduction: 
 
Oral cancer affects as many as 274,000 people worldwide annually1.  Oral cancer 
is the sixth most common cancer in the world2.  The most common type of oral cancer is 
squamous cell carcinoma1. 
The incidence of oral cancer is more than 30 per 100 000 population in India3.  
Oral cancer represented 14% of all cancer cases at the Regional Cancer Centre (RCC), 
Kerala. It constituted 17% of all cancers in males and 10.5% of all cancers in females, 
making it the most common cancer in males and the third most common cancer among 
females4.   Approximately 20,000 new cases of cancer of the oral cavity are diagnosed 
each year and there are about 4000 deaths due to the same annually in the US5.  
The relatively small number of deaths is offset by the severe functional and cosmetic 
disabilities that many of these patients endure in coping with their disease, which is 
primarily preventable. Unfortunately, when first seen, most patients have an advanced 
tumor, partly because of self neglect and partly because of the primary physician’s lack 
of training in the early detection of oral cancer6. 
Oral cancer detected early may be amenable to complete cure, while on the 
contrary, the presence of lymph nodal and distant metastasis drastically decreases 
survival by 50%. 30 Moreover, despite adequate local and nodal treatment, recurrences 
are known to occur. The key to surviving oral cancer is early detection and treatment6. 
 
Lymph nodal metastasis in oral cancers has been well studied. The lymph nodal 
status in the TNM staging (AJCC 2002) oral cancers subdivides the draining lymph 
nodes into seven specific sites Level I to Level VII. The neighboring lymph nodes are 
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clubbed in the “other groups” – Sub occipital, retropharyngeal, facial, 7etc. Metastasis to 
the facial node is infrequently documented; because of this, these nodes have received 
little attention in the literature. Recent literature review8 reveals that the facial node may 
be associated with recurrence and poor prognosis.  This study is reveals our experience 
with oral carcinoma with facial node metastasis. 
Facial node involvement in head and neck cancer is rarely documented. It has 
been suggested by Sheehan that the facial node may serve as a first echelon node in head 
and neck squamous cell carcinoma8.  Palpable cervical lymphadenopathy is generally 
considered as lymph nodal metastasis. It has been our experience to note the presence of 
a palpable facial node often in oral malignancies. These are patients with poor oral 
hygiene.  In a few cases it is the only node palpable. Palpation of the neck, with a 
sensitivity and specificity of 60% to 80%, is not a very accurate way to search for 
cervical metastases9. 
Does the presence of a palpable facial node contribute to the N staging of the 
cancer – particularly in view of ongoing oral sepsis? What is the significance of the facial 
node metastasis and its implication in the treatment and the prognosis of the patient?  
These are a few questions that have yet to be answered unequivocally. 
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Review of literature: 
 
 
Anatomy: 
The oral cavity extends from the cutaneous vermilion junction of the lips to the 
junction of the hard and soft palate above and to the line of the circumvallate papillae 
below10. It is divided into the lips, buccal mucosa , upper and lower alveolar ridges, 
retromolar trigone, floor of the mouth, hard palate and the anterior two thirds of the 
tongue. 
Lymphatics of the oral cavity: 
Several important groups of lymph nodes act as first echelon nodes in the oral 
cavity.  Two or three submental nodes lie on the mylohyoid muscle in the submental 
triangle. This triangle is bounded by the anterior bellies of the digastric muscles and the 
hyoid bone. Six or more submandibular nodes lie on the anterior surface of the 
submandibular gland or between the gland and the lower jaw adjacent to the facial artery.  
The nodes on the surface of the gland are preglandular nodes. Those that extend upward 
along the course of the facial artery and are divided into prevascular and retrovascular 
nodes, depending on their relationship to the facial artery. 
Another important first- echelon nodal group that receives afferent vessels from 
the oral cavity is the upper deep jugular nodes located along the upper internal jugular 
vein between the levels of the digastric and omohyoid muscles. The uppermost node is 
the jugulodigastric or tonsillar node; the lowest is the jugulo-omohyoid node. The 
jugulocarotid node, the principal node of the tongue, is located between these nodes just 
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below the level of the greater horn of the hyoid bone at the level of the bifurcation of the 
common carotid artery. Additionally but less common nodal groups receiving primary 
lymphatics from the oral cavity include the lateral retropharyngeal lymph nodes and 
nodes adjacent to the inferior portion of the parotid (periparotid nodes). 
In general, regional metastatic squamous cell carcinoma of the oral cavity 
demonstrates an orderly progression from neck nodes located in the upper regions of the 
neck towards nodes in the lower region. Malignancies of the lips and anterior floor of the 
mouth as well as adjacent gingival and buccal mucosa tend to metastasize to 
submandibular lymph nodes first. Tumors situated more posteriorly in the oral cavity 
usually metastasize initially to the upper deep jugular lymph nodes.  As multiple cervical 
nodes become involved with metastatic disease, spread to the middle and lower deep 
jugular nodes occur. It is unusual for a single metastatic node from an oral cavity cancer 
to metastasize to the lower or posterior cervical nodes initially. However, there are 
lymphatics channels that directly connect oral cavity sites with lower jugular nodes, 
which provide an anatomic basis for lower jugular lymphadenopathy. 
The Facial node 
 
Rouviere described a lymphoid “collar” of nodes, the pericervical ring that 
encircles the neck at the junction of the head and neck11. He classified the lymph nodes of 
the head and neck into 10 groups. The nodes in this collar group include the occipital, 
mastoid, parotid, facial, retropharyngeal, submaxillary, submental, and sublingual nodes 
(figure 1). Anterior and lateral cervical groups are descending chains that extend from 
this collar down along the front and sides of the neck, respectively. 
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                     Figure 1.  Lymph nodes of the neck.
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            The facial nodes were one of the most inconsistently present groups in the head 
and neck region.  These are lymph nodules intercalated along the course of the lymphatic 
vessels that drain the face. These nodes are found along the course of the branches of the 
facial vessels in the subcutaneous spaces of the face. Most of the afferent drainage is 
from the skin and subcutaneous tissues of the face and the mucosal surface of the gums. 
The efferent drainage is primarily to the submandibular lymph nodes. 
Rouviere divided the facial nodes into four groups. These groups are the inferior 
maxillary nodes (referred to as the mandibular nodes), buccinator nodes, infraorbital or 
nasolabial nodes, and malar nodes. To this classification, Tart 12added an additional 
group of lymph nodes designated as the retrozygomatic nodes.  
Mandibular Nodes  
Synonyms for this group include supramaxillary nodes, supramandibular nodes, 
and inframandibular nodes. These nodes, when present, lie along the external surface of 
the mandible adjacent to the facial artery and anterior to the masseter muscle12, 13. Most 
commonly one node is present, but there may be as many as three. These nodes are deep 
to the superficial muscles of facial expression ( figure 2).  One additional node that may 
be a part of this group (the inferior maxillary node or inframaxillary node) does lie in the 
subcutaneous tissues near the inferior margin of the mandible. 
The afferent drainage is from the infraorbital and buccinator lymphatics as well as from 
the skin and subcutaneous tissues of the cheek, lower tip, and less commonly the gingiva. 
The efferent drainage is to the submandibular lymphatics. 
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Figure 2. Diagram illustrating the locations of the facial nodes.  
 
 
 
 
 
A, The skin and subcutaneous fat have been removed, revealing the more superficial 
facial nodes, including the mandibular, buccinator, malar, and infraorbital nodes. 
 B, The superficial muscles of facial expression and the sternocleidomastoid muscle 
have been removed, demonstrating the relationship of the facial nodes to the facial veins.  
C, The masseter muscle has been removed, as has the zygomatic arch, revealing the 
retrozygomatic and buccinator nodes. 
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Buccinator Nodes 
The buccinator nodes are found lying on the buccinator muscle on in the fat of the 
buccinator space.  They are divided into two groups according to their relationship to the 
anterior facial vein. The anterior nodes lie anterior on superficial to the facial vein, and 
the posterior nodes lie posterior or deep to the facial vein.  Usually one or two nodes may 
be found in either location. One separate node may rarely be found more anterior in the 
subcutaneous fat adjacent to the angle of the mouth.  The afferent drainage is from the 
skin and subcutaneous tissues of the lower lid, nose, cheek, and rarely the temporal 
region. The infraorbital, malar, and possibly retrozygomatic nodes drain by this pathway. 
The efferent drainage is by the mandibular lymphatics to the submandibular nodes. 
Infraorbital Nodes 
In the canine fossa or nasolabial fold, there is usually one node lying along the 
course of the anterior facial vessels. This lymph node has been designated the infraorbital 
node. Lymphoma has a propensity for involving this region, and in most cases the lymph 
tissue is adherent to the infraorbital neurovascular bundle. 
The afferent drainage is from the skin and subcutaneous tissues of the medial eye, 
nasolabial fold, and nose.  The efferent drainage is to the buccinator and mandibular 
lymphatics. 
Malar Nodes 
The Malar nodes have been described as those lymph nodes found superficial to 
the malar eminence just lateral to the eye. These nodes are intercalated along the vertical 
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lymphatic channels coursing from the parotid over the zygomatic arch to the temporal 
region. Therefore, there is a spectrum of possible locations for these nodes, from the 
malar eminence to the end of the zygomatic process of the maxilla. 
The afferent drainage is from the skin and subcutaneous tissues of the lids, lateral 
canthus region, and temporal region. The efferent drainage is to the parotid nodes, unlike 
the nest of the facial nodes, which drain to the submandibular group. In fact, a useful 
landmark is the lateral canthus of the eye; the tissues lateral and posterior to the lateral 
canthus usually drain via the parotid lymphatics. 
Retrozygomatic Nodes 
These nodes are found deep to the zygomatic arch in the infratemporal fossa just 
at the posterior margin of the maxillary sinus.  The afferent lymphatic drainage is from 
the tissues of the deep temporal and infratemporal fossa. The efferent drainage is most 
likely via the facial lymphatics through the buccinator space. 
 
Lips:  
The lips begin at the junction of the vermilion border with the skin and form the 
anterior boundary of the oral vestibule. The lip includes only the vermilion surface, or 
that portion of the lip that comes into contact with opposing lip. The lymphatic drainage 
of the lips has been well described. The upper and lower lips have a cutaneous and a 
mucosal system of lymphatics, both arising from a fine capillary network beneath the 
vermilion border, the medial portion of the lip drains to submental lymph nodes, whereas 
the lateral portion drains into submandibular lymph nodes. Numerous anastomoses form 
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the lymphatic vessels of the two lip halves are present near the midline and account for 
bilateral metastases from tumors that are close to or cross the midline. Collecting 
lymphatic trunks have been shown to enter the mental foramen in 22% of lip cancer 
cases. The upper lip lymphatics drain to preauricular, infraparotid, submental lymph 
nodes. In contrast to the lower lip, only a few of the upper lip cutaneous lymph trunks 
drain to contralateral nodes. No crossing of the midline has been documented for the 
mucosal lymphatics of the upper lip. Lymphatic channels from nodes located in the 
submental, submandibular. And periparotid areas drain into the lymph nodes of the upper 
and occasionally the middle deep jugular lymphatic chain. 
Buccal mucosa:   
The buccal mucosa includes the entire membrane lining of the interior surface of 
the cheek and lips, from the opposing lip’s line of contact to the pterygomandibular raphe 
posteriorly and to the line of attachment of the alveolar ridge mucosa above and below. 
The buccal mucosa forms the lateral wall of the oral vestibule. Tumours of the buccal 
mucosa may extend laterally through the buccinator muscle to involve the buccal fat pad 
posteriorly or subcutaneous tissues and skin of the cheek.  
Lymphatics of the buccal mucosa arise from a submucosal network and drain to lymph 
nodes located in the submental and submandibular triangles.  
Upper and lower alveolar ridges:  
  The alveolar ridges include the alveolar processes of the mandible and maxilla 
and their mucosal covering that, in the case of the lower alveolar ridge, extends from the 
line of attachment of mucosa in the buccal gutter to the line of the free mucosa in the 
floor of the mouth. Posteriorly, the lower alveolar ridge’s mucosa extends to the 
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ascending ramus of the mandible.  The upper alveolar ridge’s mucosa extends from the 
line of attachment of mucosa extends from the line of attachment of mucosa in the upper 
buccal gutter to the junction of the hard palate. Its posterior margin is the upper end of the 
pterygopalatine arch.  
Lymphatics of the buccal aspect of the upper and lower alveolar ridges drain into 
the submental and submandibular lymph nodes.  Lymphatic from the lingual aspect of the 
upper and lower gingival pass chiefly to upper deep jugular and lateral retropharyngeal 
lymph nodes. Some channels may drain to lymph nodes adjacent to the tail of the parotid 
gland (subparotid). Lymphatics from the lingual surface of the lower alveolus also may 
end in submandibular nodes. 
Retromolar trigone: 
The retromolar trigone is the attached gingival overlying the ascending ramus of 
the mandible. The distal surface of the last lower molar forms the base of this triangular 
area, and its apex terminates at the maxillary tuberosity.  The upward extension of the 
oblique line of the mandible to the coronoid process forms the triangle’s lateral side, and 
a line connecting the distal lingual cusp of the last molar and the coronoid process forms 
the medial side. The triangle’s base is continuous laterally with the gingivobuccal sulcus 
and medially with the gingivolingual sulcus. The triangle’s lateral side is continuous with 
the buccal mucosa and the medial side blends into the anterior tonsillar pillars. 
The lymphatic drainage of the retromolar trigone is similar to that of the tonsillar 
fossa, passing to the upper deep jugular chain of lymph nodes. Some lymph channels may 
also end in subparotid and lateral retropharyngeal lymph nodes. 
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Hard palate: 
  The hard palate is a semilunar area consisting of mucous membranes covering the 
horizontal laminae of the palatine bones. The upper alveolar ridge partly surrounds the 
hard palate, which extends from the inner surface of the superior alveolar ridge to the 
posterior edge of the palatine bone. Two or more foramina are located posterolaterally on 
either side near the junction of the hard or soft palate. The larger is the greater palatine 
foramen, and behind this are one to two lesser palatine foramina. The foramina represent 
the lower end of the pterygopalatine canal, through which nerves and vessels are 
conducted from the pterygopalatine fossa and regions of the skull base. Likewise, the 
incisive fossa and canal provide a pathway for tumor extension into the nasal cavity.  
Similar to the alveolar ridge, the periosteum of the hard palate adheres more intimately to 
the mucosa than to the bone; thus, the two are referred to as the mucoperiosteum. The 
mucoperiosteum acts as a temporary barrier to the deep spread of tumor; however, 
cancers of the hared palate frequently extend into the underlying bone as the disease 
progresses 
Lymphatics of the hard palate are sparse compared with other sites in the oral 
cavity. Drainage is similar to that of the lingual surface of the upper alveolus.  Most of 
the lymphatics drain into upper deep jugular or lateral retropharyngeal nodes. Lymph 
channels draining the primary palate may terminate in the prevascular and retrovascular 
group or submandibular nodes. 
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Floor of mouth:  
The floor of mouth is a crescent-shaped region of mucosa overlying the 
mylohyoid and hyoglossus muscles, extending from the inner aspect of the lower alveolar 
ridge to the underside of the anterior two thirds of the tongue. Posteriorly, the floor of the 
mouth is continuous with the base of the tonsillar pillar, and anteriorly the frenulum of 
the tongue divides it into two sides.  
The lymph vessels of the floor of the mouth spring form an extensive submucosal 
plexus that forms two discrete systems: a superficial mucosa and a deep collecting 
system.  The superficial system has crossing afferent lymphatic vessels in the anterior 
floor of the mouth, where no definite midline exists. These channels drain into the 
ipsilateral and contralateral preglandular lymph nodes. The deep collecting system drains 
into the ipsilateral preglandular lymph nodes. Only the most anterior collecting vessel of 
the deep system crosses the midline. Lymph channels from the posterior portion of the 
floor of the mouth drain directly into the jugulodigastric and jugulocarotid nodes. 
Anterior two thirds of the tongue: 
The anterior two thirds of the tongue, known as the oral tongue, are considered a 
part of the oral cavity. The oral tongue is the freely mobile portion of the tongue that 
extends anteriorly from the line of the circumvallate papillae to the root. The root of the 
tongue is the undersurface at its junction with the floor of the mouth. The oral tongue 
consists of four anatomic regions; the tip, the lateral borders, the dorsum, and the 
undersurface. The base of the tongue is that portion posterior to the circumvallate papillae 
and is considered a structure of the oropharynx. 
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Figure 3.  Lymphatic drainage of the tongue.  
 A,  Right lateral aspect.  Each cross-hatched circle represents a group of nodes.  JD, 
jugulodigastric nodes;  JOH, jugulo-omohyoid nodes.  
B, Schematic coronal section. (A is based on Rouviere, B on Jamieson and Dobson.) 
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Lymphatics of the tongue: 
Lymphatics of the tongue arise from an extensive submucosal plexus, and all 
vessels drain ultimately into the deep jugular lymph nodes between the levels of the 
digastric and omohyoid muscles. The nearer the tip of the tongue the lymphatics arise, the 
lower is the first echelon node; and the farther posterior, the higher the node (figure 3). 
Lymphatic collecting channels of the tongue are the anterior (apex), lateral (marginal), 
central and posterior groups. Vessels from the apex pierce the mylohyoid to end in 
submandibular nodes. The remaining trunks drain on either side of the hyoglossus muscle 
to deep jugular nodes. Lymph channels from the tongue base pass through the pharyngeal 
wall laterally below the tonsil to reach principally the jugulodigastric nodes.  
Cancer of the tongue frequently metastasizes bilaterally, primarily because of the 
rich lymphatics in the submucosal plexus, which freely communicate across the midline. 
In addition, collecting lymphatic trunks from the apex, central, and posterior groups have 
many collecting channels that cross over to terminate in contralateral lymph nodes. 
Gross pathology 
 
 The gross morphologic growth patterns of squamous cell carcinoma (SCC) that 
occur in the oral cavity are exophytic, ulcerative, and infiltrative10. The exophytic form is 
the least common, except on the lip. It tends to grow more superficially and metastasize 
later than the other types. This form begins as an area of thickened epithelium, which 
heaps up and can protrude 1 cm or more above the surrounding mucosa. Ulceration 
occurs early in its development. Exophytic carcinomas gradually become deeply 
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infiltrative in more advanced cases. On the lip this form of tumor may reach a size of 6 or 
7cm, with little local destruction of tissue. 
 The ulcerative type is the most common form of SCC in the oral cavity. It begins 
as a round or oval ulcer with a gray, shaggy base that bleeds readily. Ulcerative types 
manifest a greater tendency for rapid infiltration and usually have a higher histologic 
grade than the exophytic type. The ulcer eventually may heap up and become exophytic 
or remain lower than surrounding mucosa.  
 Infiltrative malignancies are common in the tongue and initially appear as a firm 
mass or plaque covered by mucosa. This type of tumor extends deeply into underlying 
tissues, with minimal elevation above the surrounding mucosa. As the neoplasm 
progresses, ulceration and exophytic manifestations may be observed. 
 A fourth morphologic type of oral cancer is verrucous carcinoma, which is clearly 
defined but uncommon variant of SCC. It typically occurs in elderly patients who have 
poor oral hygiene or ill-fitting dentures and most commonly affects the buccal mucosa of 
men and women with a history of tobacco chewing or snuff dipping. The tumor has a 
warty, bulky, elevated, and fungating appearance. It does not invade deeply into 
underlying tissue. Verrucous carcinomas have an indolent behavior and do not 
metastasize. The characteristic histologic pattern is an undulating, densely keratinized 
outer layer covering large papillary fronds and a sharply circumscribed, deep margin 
composed of rows of bulbous, well-oriented rete ridges. The advancing margin appears to 
push through rather than invade and infiltrate deep tissue. 
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Histopathology 
Broders14 classified tumors into one of four groups depending on cellular 
differentiation, as based on the percentage of total cellular elements.  The presence of 
minimal pleomorphism and few mitoses indicated a well differentiated grade I neoplasm. 
Poorly differentiated neoplasms show extreme pleomorphism, minimal or no 
keratinization, and frequent mitoses and are classified as grade IV.  Most oral cavity 
cancers are grade I or II. 
  
Regional metastases 
 Regional metastases portend a worse prognosis for patients with oral cancer.  The 
5-year survival rate in patients with cervical metastasis is approximately 50% lower than 
that in patients without clinical evidence of metastases. The prognosis is further worsened 
in patients with multiple cervical metastases.  In addition to the correlation of clinical 
metastases with decreased survival, histopathologic evaluation of the metastatic lymph 
nodes is also significant.  Patients found to have extracapsular spreads of carcinoma in 
cervical lymph nodes have been shown to have a statistically lower rate of survival. 
Despite the extracapsular spread being directly related to the size of cervical nodes, it is 
apparent that spread is more common in small (N1) cervical nodes than previously 
appreciated. Extracapsular spread may indicate depressed immunologic surveillance and 
failure to contain tumor spread.  Several studies indicate that the survival rate of patients 
with cervical metastases where the tumor is limited to the node ranges from 50% to 70% 
for 5 years.  If extracapsular spread of neoplasm occurs, however, 5-year-survival is 
reduced to less than 30%10. 
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 Regional metastases are present on initial evaluation in approximately 30% of 
patients with oral cavity cancer, excluding cancers of the lip and hard palate.  The 
incidence of regional metastases is related to the size of the primary tumor, with larger 
tumors manifesting a higher incidence.  Contralateral or bilateral metastases may develop 
when the primary tumor is near or crosses the midline.  Approximately 25% of patients 
who show no evidence of regional metastases when first evaluated will eventually 
develop nodal disease despite control of their original primary tumor. 
 Clinically apparent cervical lymph node metastases occur in 10% to 15% of 
patients with SCC of the lip15 and 15% to 25% of patients with cancer of the hard 
palate16. Subsequent development of regional metastases following control of lip cancer 
ranges from 5% to 15%.  The lower incidence of metastases from hard palate tumors is 
related to the rather sparse lymphatic supply to this region.  The lower metastatic rate of 
lip cancer occurs because most lip cancers are small and well differentiated when first 
evaluated. 
Distant metastases 
 Distant metastasis of the tumor eventually occurs in 15% to 20% of patients dying 
of oral cavity cancer.  In such instances regional cervical metastases have been present 
for prolonged periods.  Disseminated neoplasm affects bone and lungs most frequently. 
Multiple primary neoplasms 
 The occurrence of multiple primary neoplasms in patients with head and neck 
cancer is believed to be as high as 39%.  These tumors are described as simultaneous if 
diagnosed with the primary tumor and synchronous, if diagnosed within 6 months after 
 25 
diagnosis of the primary tumor. The frequency of second primary tumors in patients with 
oral cancer in the upper aeordigestive tract is approximately 18%17 in 50% to 70% of 
cases and is related to the effects of alcohol and tobacco on the mucosa. Patients at the 
greatest risk of developing a second primary tumor are those who smoke and drink 
heavily for many years. The risk of developing additional malignancies in patients who 
discontinue smoking after control of their first malignancy is one sixth the risk for those 
who continue to smoke. However, this risk does not appear to decrease until 5 years after 
ceasing the habit, suggesting that carcinogenic factors are long-term influences. The 
greatest risk of developing a second primary tumor occurs within the first 3 years after 
therapy for the first cancer. 
MANAGEMENT OF ORAL CANCERS 
 
Symptoms: 
The most common symptom of the cancer of the oral cavity is a persistent ulcer in 
the mouth. The diagnosis is frequently delayed, however, probably because pain 
associated with ulceration occurs rather late in the course of disease.  Dentists may see 
the patients first because of loosening of the teeth or pain around the teeth or in the jaw. 
Occasionally, dysphagia may be present, particularly if the tumor is located in the 
posterior oral cavity or is extending into the oropharynx.  A neck mass is seen in one 
third of patients.  
 
Clinical examination: 
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Physical examination is the key to diagnosing and evaluating oral cavity cancer. 
A thorough inspection of the oral cavity along with bi-digital palpation assists the 
surgeon in assessing the extent of the tumor, particularly in the tongue musculature and 
the floor of the mouth. Pharyngoscopy and laryngoscopy is performed to evaluate the 
tumor’s extension into regions of the oropharynx. Evaluation of the neck for possible 
cervical lymph node metastases is essential.  Physical examination of the neck remains 
the most common method of staging neck disease.  However, palpation has been reported 
to have a sensitivity of only about 75%.  Sensitivity is increased with the use of imaging 
studies.  
The division of the neck nodes into 7 regions (figure 4) as described at Memorial 
Sloan-Kettering is accepted universally.   These are: 
1.  Level 1, containing the submental and submandibular nodes.     
2.  Level 2, containing the upper third of the jugular nodes medial to the 
sternocleidomastoid muscle has, as its inferior boundary, the plane of the hyoid bone 
(clinical) or   the bifurcation of the carotid artery (surgical). 
3.  Level 3, containing the middle jugular nodes, is bounded inferiorly by   the plane of 
the cricoid cartilage, (clinical) or the omohyoid (surgical). 
4.  Level 4, containing nodes in an area defined superiorly by the omohyoid muscle and 
inferiorly by   the clavicle. 
 5.  Level 5, containing the nodes in the posterior cervical triangle. 
6.  Level 6, containing the nodes in the paratracheal and pretracheal area.  
7.  Level 7, containing the nodes along the tracheoesophageal groove and superior 
mediastinum. 
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Figure 4.  Division of Lymph nodes of the neck 
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Radiological evaluation: 
Radiological imaging is an important adjunct in assessing oral cavity carcinoma 
that encroaches on the mandible or involves the hard palate.  Conventional radiography, 
including an orthopantomogram, is helpful in determining invasion of bone.  As many as 
30% of patients with an oral cavity malignancy cancer encroaching on the mandible with 
normal radiographic finding have microscopic invasion of bone. Bone scanning with 
technetium-99mphosphate is sensitive enough to be positive in bone involved with tumor 
before these lesions can be detected by conventional radiographic examination.  
However, specificity to differentiate between tumor, infection, trauma, and inflammation 
is lacking. 
Computed tomography (CT) is helpful in assessing soft tissue and bony extension 
of the tumor. CT and magnetic resonance imaging have an approximately equal 
sensitivity (85% to 95%) for diagnosis of nodal metastases18.  Ultrasound evaluation can 
identify lymph nodes not palpable by clinical examination.  The criteria used to define a 
pathologic node will vary the sensitivity and specificity of this technique. Criteria 
allowing the sensitivity of about 90% can result in specificity as low as 30%.   Fine-
needle aspiration cytology can be combined with ultrasound to increase its specificity to 
90%.19Positron Emission Tomography is a recent imaging modality being used in the 
management of oral malignancies.  Comparison between PET and standard techniques 
revealed that PET had an accuracy of 82%, CT 84%, and physical examination 71%20. 
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Staging of Oral Carcinoma: 
The American Joint Committee on Cancer Staging (AJCC 2002) recommended 
the following TNM Staging for head and neck malignancies. 
 
TNM definitions  
  
Primary tumor (T)  
TX: Primary tumor cannot be assessed  
T0: No evidence of primary tumor  
Tis: Carcinoma in situ  
T1: Tumor ≤2 cm in greatest dimension  
T2: Tumor >2 cm but ≤4 cm in greatest dimension  
T3: Tumor >4 cm in greatest dimension  
T4: (lip) Tumor invades through cortical bone, inferior alveolar nerve, floor of mouth, or 
skin of face, i.e., chin or nose  
T4a: (oral cavity) Tumor invades adjacent structures (e.g., through cortical bone, into 
deep [extrinsic] muscle of tongue [genioglossus, hyoglossus, palatoglossus, and 
styloglossus], maxillary sinus, and skin of face)  
T4b: Tumor invades masticator space, pterygoid plates, or skull base and/or encases 
internal carotid artery 
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Regional lymph nodes (N) 
NX: Regional lymph nodes cannot be assessed  
N0: No regional lymph node metastasis  
N1: Metastasis in a single ipsilateral lymph node, ≤3 cm in greatest dimension  
N2: Metastasis in a single ipsilateral lymph node, >3 cm but ≤6 cm in greatest dimension; 
or in multiple ipsilateral lymph nodes, ≤6 cm in greatest dimension; or in bilateral or 
contralateral lymph nodes, ≤6 cm in greatest dimension  
N2a: Metastasis in a single ipsilateral lymph node >3 cm but ≤6 cm in dimension  
N2b: Metastasis in multiple ipsilateral lymph nodes, ≤6 cm in greatest dimension  
N2c: Metastasis in bilateral or contralateral lymph nodes, ≤6 cm in greatest dimension  
N3: Metastasis in a lymph node >6 cm in greatest dimension  
 
 
Distant metastasis (M)  
MX: Distant metastasis cannot be assessed  
M0: No distant metastasis  
M1: Distant metastasis  
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AJCC stage groupings  
Stage 0 
• Tis, N0, M0  
Stage I 
• T1, N0, M0  
Stage II 
• T2, N0, M0  
Stage III 
• T3, N0, M0  
• T1, N1, M0  
• T2, N1, M0  
• T3, N1, M0  
Stage IVA 
• T4a, N0, M0  
• T4a, N1, M0  
• T1, N2, M0  
• T2, N2, M0  
• T3, N2, M0  
• T4a, N2, M0 
Stage IVB 
• Any T, N3, M0  
• T4b, any N, M0 
Stage IVC 
• Any T, any N, M1  
 
 
 
Treatment 
 The therapeutic modalities include surgical excision, radiotherapy, chemotherapy, 
or a combination of these modalities. The treatment employed depends on the tumor’s 
extent and location, the patient’s physical and social status, and the physicians experience 
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and skill. Generally, either surgery or irradiation is successful in controlling small tumors 
confined to the site of origin (stage I & II). The main advantage of radiotherapy is the 
avoidance of surgery, anesthesia and their associated risks. Radiotherapy is particularly 
advantageous for ill-defined neoplasms located posteriorly that make surgical exposure 
and resection more difficult. The major disadvantage of radiotherapy is the often 
permanent xerostomia and dysgeusia. Full-mouth tooth extractions may be required 
before instituting therapy to avoid the risk of progressive deterioration of the teeth and 
the development of osteoradionecrosis. 
Small, anteriorly located cancers of the oral cavity may be amenable for surgical 
resection. The surgical defect may be closed primarily, skin grafted, or allowed to heal by 
secondary intention without significant functional impairment. The advantages of surgery 
include the avoidance of xerostomia and the rapid rehabilitation of the patient. The major 
disadvantage is the functional disability, which is directly related to the extent of 
resection of the mandible or tongue. 
 
Radiotherapy  
 There are four principles governing the use of radiotherapy in the management of 
oral cancer:  
(1) Most squamous cell carcinomas are radio-responsive, although high doses of radiation 
are required for local control. 
 (2) Well-oxygenated neoplasms are more radio-responsive than hypoxic neoplasms. 
(3) Bone or deep muscle invasion decreases radiocurability. 
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(4) Large cervical metastases are better managed by neck dissection, with or without 
adjunctive radiotherapy. 
 Radiotherapy is indicated when survival is equal to, and morbidity is less than 
surgery alone or combined therapy. Radiotherapy can be given as external-beam 
management, interstitial therapy (brachytherapy), or a combination of the two. The total 
dose of radiotherapy for oral carcinomas is usually in the range of 65 to 75 Gy. The dose 
may be modified according to the tolerance level of the patient. The goal is to maximize 
local control but minimize complications such as osteoradionecrosis. 
 Conventional fractionation external-beam radiotherapy is usually administered at 
a dose of 1.8 to 2.0Gy per fraction five times per week. The fractionation schedule may 
have a significant impact on locoregional control. Fraction size is known to be the major 
factor in determining late effects or complications.  Hyperfractionation involves smaller 
than conventional dose fractions given twice a day to a greater total dose.  . 
 Interstitial irradiation (brachytherapy) is frequently used in combination with 
external radiotherapy to treat cancers of the tongue and floor of the mouth. Much larger 
doses are given to the tumor than to the surrounding region with use of temporary 
implants of iridium-192 via hollow catheters and afterloading techniques. 
 
Prophylactic neck irradiation 
 Occult metastases consist of microfoci tumors in cervical nodes that are not 
clinically detectable. The incidence of occult metastases varies with site and size of the 
primary tumor in the oral cavity and ranges from 15% to 60%. Prophylactic neck 
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irradiation can be used for the treatment of occult metastases. Reports indicate that 
radiotherapy of the clinically negative neck to a level of 50 to 55 Gy controls occult 
disease and prevents late occurrence of cervical metastases21.  When the primary cancer 
of the oral cavity remains controlled, development of cervical nodal disease is less than 
5% in patients undergoing prophylactic neck irradiation. This statistic is in contrast to an 
expected 25% failure rate in patients initially having N0 classified necks and receiving no 
neck treatment22. 
 Prophylactic irradiation of the neck relieves the patient of the functional and 
cosmetic deformity of neck dissection. Neck fibrosis is not a serious problem when 50Gy 
administered over 5 weeks. However, xerostomia may occur as a result of encompassing 
submandibular and parotid glands in the irradiated fields. Although prophylactic neck 
irradiation appears to be at least as effective as elective neck dissection in the 
management of occult neck disease, prospective randomized studies are needed for 
conclusive evidence on support of one modality or the other. 
 
Surgery 
 Local surgical excision may be used for malignancies of the oral cavity measuring 
2 cm or less. Carcinomas of the oral cavity with invasion of the mandible are less 
radiocurable than are neoplasms confined to soft tissue. Thus, when a neoplasm directly 
invades the mandible, surgery is the preferred treatment.  Surgery is also indicated in 
advanced tumors of the oral cavity.  
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 The high incidence of microscopic invasion of the periosteum and cortical layer 
of the mandible even with normal radiographic findings has warranted guidelines for 
surgical management of the mandible. Tumors that encroach on the mandible and do not 
provide a margin of 1.5 cm of normal tissue between tumor and bone usually require 
resection of at least a portion of the mandible. Depending on the location of the 
neoplasm, a marginal resection of the upper portion of the mandible or resection of the 
inner or outer cortical plate of the jaw may provide and adequate margin around the 
tumor while still preserving mandibular continuity. Direct invasion of the mandible 
requires a full-thickness segmental resection of the mandible. 
 Surgery is also indicated in patients who have completed a full course of 
radiotherapy and demonstrate persistent tumor or suffer recurrence at the primary site or 
in the neck. Incomplete healing of the primary site immediately following full-course 
radiotherapy should be observed closely, allowing 8 to 12 weeks to elapse before biopsy. 
If tumor is persistent, en bloc resection is indicated, including the entire area of the 
original tumor. If clinically positive lymphadenopathy was present before irradiation, 
neck dissection is also performed. If radiotherapy controls the primary tumor but the 
patient continues to have palpable lymphadenopathy, neck dissection without resection of 
the primary site is indicated.  
 
 
Neck dissections 
 Patients with clinically negative necks but extensive primary lesions ( T3,or T4) 
have a high probability of neck metastases. Selective en block removal of the lymph 
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nodes most likely to harbor metastases is performed by a supraomohyoid neck dissection 
(zone I, II and III). Patients with no evidence of metastases have improved regional 
control of disease with the addition of radiotherapy. 
 Patients with clinically detectable neck disease (N1, N2, or N3) require a neck 
dissection for optimal disease control. A modified neck dissection sparing the spinal 
accessory nerve (MRND I) is performed if the neck disease is not in the proximity of the 
nerve. Patients with clinically detectable neck disease should undergo postoperative 
radiotherapy to optimize regional disease control.  
 Lesions located in the midline may cause bilateral metastases. It is therefore 
important to address both sides of the neck. If both are clinically N0, bilateral 
supraomohyoid neck dissections can be performed as staging procedures. Bilateral neck 
dissections should be performed if bilateral disease is noted. 
 
Combined therapy 
 Most physicians have advocated the combination of radiotherapy and surgery in 
treating advanced stage III and IV disease of the oral cavity in hopes of reducing local 
recurrence and improving survival rates. Postoperative radiotherapy has also been shown 
to be effective in increasing loco-regional control in advanced (stage III or IV) squamous 
cell carcinoma of the oral cavity23. 
Chemotherapy 
Chemotherapy given before other methods of treatment is called neoadjuvant or 
induction chemotherapy. Adjuvant chemotherapy involves the use of chemotherapy in 
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conjunction with other treatments. A variety of agents have been used, including 
cisplatin, 5-fluorouracil, methotrexate, bleomycin, paclitaxel and topotecan. 
 Chemotherapy agents can also be given concurrently with radiotherapy.   This 
may result in a radiosensitizing effect and improved loco-regional control. Trials have 
shown improvement in local control with a trend toward survival, but with significantly 
increased toxicity. 
Follow up: 5- year survival 
 
Cure rates for carcinoma lip T1 and T2 lesions without cervical metastasis is > 
90%.  With regional metastasis the five year survival drops to 50%. The five year 
survival rate for stage I and II lesions of Carcinoma tongue amounts to 82% while it is 
49% for stage III and IV.  In a patient with Carcinoma of the floor of the mouth, the 5 
year survival rate is 88% for stage I lesions while it is 32% for stage IV tumours.  For 
carcinoma buccal mucosa and alveolus, stage I disease has a 5 year survival of 75 and 
77% respectively and stage IV is 20 and 24 % respectively.  Distant metastasis and 
recurrence have worse prognosis in any site10. 
 
Facial nodes are the lymph nodes found along the course of the branches of the 
facial vessels of the face, above the level of the margin of the mandible.  The facial nodes 
are continuous inferiorly with the prevascular and retrovascular lymph nodes of the neck 
and the latter have been often incorrectly termed as facial nodes8. 
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 Rouviere classified them into 4 groups based on their site viz. malar, infraorbital, 
buccinator and mandibular8, 24, 25.  Tart12 added another group to these nodes – 
retrozygomatic. 
These nodes receive afferent lymphatics draining the skin, subcutaneous tissues of 
the face. In addition they have been described to drain the buccal and gingival mucosa as 
well.  The efferent drainage is to the submandibular lymph nodes. 
Facial nodes may be involved in metastatic or primary head and neck cancer. There have 
been several reports of its involvement. These reported primary malignancies include 
squamous cell or adenocarcinoma of the maxillary sinus, nasopharyngeal carcinoma, 
tongue, lip, buccal mucosa, preauricular skin, salivary glands and the retromolar trigone. 
In adults, disease of these nodal groups may be the sole manifestation of a lymphoma27. 
Others include metastatic disease from ocular melanoma and distant sites such as bladder 
carcinoma 26, 27, 2 8. 
 
The mandibular node has also been termed as the mandibulofacial node and has 
been found to be enlarged in a number of benign conditions which include infections of 
the oral and nasal cavities.  
The facial node of most interest to the surgeon is the mandibular group, also 
called the supramandibular group. These nodes are located adjacent to the facial artery, at 
the anterior border of the masseter muscle, overlying the horizontal ramus of the 
mandible. The node of STAR described in Gray’s Anatomy, 1954, as a constant node 
which is found just where the facial artery crosses the horizontal ramus of the mandible29. 
 
 39 
Lymph nodes of the head and neck 
The facial nodes are of importance owing to their close proximity to the marginal 
mandibular nerve. Surgical techniques that are used to preserve the marginal mandibular 
nerve such as ligating the facial vein low in the neck and retracting it superiorly to 
include the nerve in the skin flap may render the removal of these nodes difficult31. 
 
Sheehan in his retrospective study of 32 hemi-neck dissections reported that 7 
patients had metastasis in the facial node, an incidence of 24%8.  He observed that facial 
node involvement was much more common with patients with palpable cervical 
lymphadenopathy. Further, facial node involvement was associated with metastatic 
cervical lymph nodal disease.  The facial node was a first-echelon node in carcinoma of 
the retromolar trigone. The mean maximum size of a metastatic facial node was (0.7 cm), 
smaller than that of a non-metastatic node (1 cm).  He did not find any significant 
difference in the T- stage of the primary tumour between patients with positive and 
negative facial nodes. A significant finding was that positive facial nodes were associated 
with an increased risk of treatment failure and a poorer survival. 
 Lymph node metastasis is a well-established negative prognostic indicator in the 
treatment of squamous cell carcinoma of the head and neck8.  The presence of lymph 
node metastasis has been shown to decrease survival by 50%30. The determination of 
whether or not the disease has metastasized to the neck is therefore of critical 
significance.  
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Imaging modalities such as ultrasound, computed tomography, and magnetic 
resonance imaging have been used in N0 neck in an effort to identify patients with occult 
nodal disease. These techniques are based primarily on size criteria, with nodes smaller 
than 10 mm not generally considered suspicious. However, nodes as small as 2.0 mm can 
contain micrometastatic disease. Other factors, such as the size, site, and depth of 
invasion of the primary tumor, as well as the presence of perineural invasion, have also 
been implicated in predicting regional metastasis. These techniques, though helpful, have 
not proved to be completely reliable, and there is still a 20% to 30% incidence of occult 
nodal metastasis in N0 necks.   It has been demonstrated that up to 46% of positive lymph 
nodes measure less than 10 mm in diameter.9 Paradoxically, nodes in excess of 20 mm 
may be histologically benign and enlarged as a result of reactive hyperplasia32. 
Most neck recurrences of oral-cavity carcinomas occur within 2 years.  Many 
studies have documented the rate of regional recurrence to be dependent on pN status: the 
rate is reported to be 2% to 7% in patients with pN0 neck and 15% to 22% in patients 
with pN neck.  Patients with neck recurrences have a poor prognosis despite salvage 
treatment.33   Regional recurrences developed in 4% and 35% of patients with pN0 and 
pN+ necks respectively.  The rate of occult lymph node metastases in patients with cN0 
neck has been reported between 11% and 45%. In patients with cN0 neck and a >20% 
probability of occult  metastases, an elective treatment of the neck for diagnostic  and 
therapeutic purposes is generally  performed33. This 20% threshold would include most 
oral cavity cancers staged T2 or higher34. 
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Studies of lymphatic drainage demonstrated that most regions of the oral cavity 
drain to neck levels I to III. Furthermore, the prevalence and distribution of lymph node 
metastases was analyzed on large histologic studies on radical neck-dissection specimens. 
These observations formed the rationale for the currently most often employed 
supraomohyoid neck dissection (SOHND) of oral cavity carcinomas in patients with cN0 
neck11. 
 
The presence or absence of occult lymph nodes is one of the major prognostic 
factors for survival in patients with clinically negative cervical lymph nodes. Most oral 
cancers are stated by physical examination and/or imaging. The sensitivity of combined 
physical examination and computed tomography scan is 85% to 90%. However, this still 
leaves a significant number of clinically N0 patients with sub-clinical neck metastases. 
Magnano et al  showed that 13.8% (38/274) of clinically N0 necks contained metastatic 
disease on histological examination of the specimen. Snyderman   et al     found that 41% 
of their patients without adenopathy had metastatic disease on histological examination.  
Khafif et al  observed  that 20% to 50% of clinically N0 patients had occult metastatic 
disease. These patients presented with clinically evident metastatic nodes within 1 to 2 
years.  Layland et al reported that 7.5% of patients who were staged clinically N0 and 
received a neck dissection as part of the treatment, were found to be pN1, and 4.5% were 
pN2.  Leemans et al demonstrated that the number and size of lymph node metastases 
relates directly to the probability of death attributable to cancer35. 
 
 
 42 
The goal of treating the neck with radiotherapy, neck dissection, or a combination 
of the two is to prevent regional recurrence.  Basic histopathological features of cervical 
metastasis such as node level, number, and size and presence of extra-capsular extension 
have been shown to be independently associated with increased risk of recurrence.  Neck 
recurrence is almost four times as likely to occur in  histopathologically N+ necks 
compared with N0 necks  (9.7% vs. 2.6%)35. 
 
In patients with locally advanced tumors (T4), clinical nodal status and 
histological nodal invasion were key prognostic factors36. 
Hence we see the importance placed on the nodal status of the patient and the 
extent one needs to pursue a line of action that accurately stages the patient for 
appropriate treatment and prognosis. Given that the metastatic involvement of the facial 
node has been reported to have a poor prognosis special attention is to be paid to the 
treatment of patients who would be at such a risk. 
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Materials and Methods: 
 
Type of study: 
This was a prospective, observational, cohort study conducted in a single surgical 
unit from September 2004 to July 2006.   
Ethics: -  
As this was only an observational study with no interventions, approval of the 
Ethics committee was not required. 
As this was an observational study, informed consent was not necessary. 
 
 
Data collection:  
Inclusion criteria:  
The study was conducted between September 2004 and July 2006. All adult 
patients with a diagnosis of squamous cell carcinoma of the oral cavity admitted for 
surgery under the department of General Surgery unit I (Head and Neck Surgery) 
between September 2004 and July 2006 were included in the study.  Patients included in 
the study were those scheduled to undergo excision of the primary lesion along with 
some form of neck dissection, either radical or selective.  In addition, only those patients 
in whom the facial node was either palpable and /or positively identified at surgery were 
included in the study.     
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Exclusion criteria: 
Children were not included in the study.  Patients with a clinically palpable facial node 
but not detectable at surgery were not included.   The patients who did not have a facial 
node identified in the surgery were not included in the study. 
Patients undergoing surgical procedures for head and neck malignancies other than oral 
cavity carcinoma were not included even if the surgical procedure involved a neck 
dissection.  Patients with oral cavity carcinoma other than squamous cell carcinoma were 
not included in the study.  Patients who had pre-operative radiation were not included in 
the study.  Patients who had neoadjuvant chemotherapy were, however included in the 
study. 
 
Demographics: 
At enrolment into the study, the patient’s name, sex, age, hospital number was 
noted.  The site of lesion with the clinical TNM staging was also noted. The presence of 
palpable facial node and neck nodes was noted. The histology of the lesion was recorded.  
If a patient was administered neoadjuvant chemotherapy, that was also noted, along with 
the type of chemotherapy and the number of cycles given. 
 
Measurement of Facial Node 
At surgery, the facial node was  dissected separately from the rest of the 
specimen.  The facial node was measured using a metal scale, taking the greatest 
dimension in centimeters as the size of the node. The facial node was then sent as a 
separate specimen for histopathological analysis. 
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The surgical procedure performed was noted.  The pathological report of the entire 
specimen included gross and microscopic description of the tumor and the number and 
involvement of neck nodes.  The microscopic involvement of facial node by tumor was 
recorded. 
Follow up 
All patients had post operative radiotherapy where indicated.  The patients were followed 
up in the out patient department, for a period ranging from 6 weeks to 1 year, depending 
upon the time of enrollment into the study.  At follow up, the patients were examined for 
recurrence of the disease in the lymph nodal region or the primary site. This was also 
recorded.   
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Results: 
 
During the period September 2004 to July 2006, 110 patients underwent a 
surgical procedure along with a neck dissection for carcinoma of the oral cavity.  Of this, 
the facial node could be positively identified in a total of 25 patients (22.7 %). 
Demographics: 
There were 19 men and 6 women.  This is depicted in figure 5. 
Fig  5.   Distribution of patients based on 
gender. (N=25)
Male 
19
76%
Female
6
24%
 
 
Site of lesion 
Most of the patients presented with carcinoma of the tongue  (44%) followed by  
carcinoma of the buccal mucosa (40 %).  These results are summarized in figure 6.  
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Fig  6.        Distribution of patients based on the 
site of Tumour. (N=25)
Carcinoma 
lower alveolus
4
16%
Carcinoma 
buccal mucosa
10
40%
Carcinoma 
Tongue
11
44%
 
TNM Staging. 
 
Majority (60 %) of the patients had locally advanced disease, with 11 (44%) of 
the patients clinically diagnosed to have T4 lesions.  Only one patient had a T1 lesion. 
The TNM staging of patients is summarized in figure 7. 
 
4%
1
36%
9
16%
4
44%
11
0
2
4
6
8
10
12
T1 T2 T3 T4
 T Stage of patients  ( N = 25)
Fig 7.    Distribution of patients based on the 
TNM Staging - T stage.
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Nodal status.
Out of the 25 patients, 9 (36 %) had no palpable nodes in the neck.  There were 11 
patients (44%) with N1 nodes.  These results are summarized in figure 8.
36%
9
44%
11
20%
5
0
2
4
6
8
10
12
N0 N1 N2
N Stage of the patients ( N = 25)
Fig 8.    Distribution of patients based on the nodal 
status
 
TNM Staging. 
Most of the patients (84 %) had advanced malignancies, either in stage III or stage 
IV.  Only 1 patient (4%) had stage I disease.  These results are summarized in figure 9. 
Fig  9.      Distribution of patients based on the 
TNM Staging. (N = 25)
Stage IV
13
52%
Stage II
3
12%
Stage I
1
4%
Stage III
8
32%
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Surgery Performed:  
A total of 25 neck dissections were performed.  Of this, over half underwent 
radical neck dissection.  Only 3 patients (12 %) underwent supra-omohyoid neck 
dissection.  These results are summarized in figure 10. 
Fig  10.      Distribution of patients with regards 
to the Neck Dissection performed. (N=25)
RND
13
52%
MRND
9
36%
SOHND
3
12%
  
Facial Node  
Histopathologically confirmed facial node involvement was present in one patient 
with carcinoma of the lower alveolus (25%) and 2 patients with carcinoma of the buccal 
mucosa (20% ). 
The facial node was clinically palpable in 11 patients (44%) and was positive for 
metastasis histologically in only three patients (12%). In contrast, of the 25 patients 
enrolled in the study, 13 (52%) had palpable cervical nodes.  At histopathological 
examination, 9 (36%) had metastatic cervical lymphadenopathy (figure 12). 
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Fig 12.   Palpable Facial and Cervical 
lymphadenopathy and their Metastatic 
involvement
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However, on closer examination of the data, only one of the 3 patients with 
metastatic facial lymph node involvement had a palpable facial lymph node (33%).  The 
other two nodes that were positive for metastasis were nodes that were not clinically 
palpable. (Figures 13,14) while 5 of the 9 (55.5%) patients with metastatic cervical 
lymphadenopathy had palpable cervical lymphadenopathy. 
 
 
 
Palpable 
 
10 
Metastatic 
 
1            2 
Figure 13.  Proportion of palpable Facial nodes that were 
metastatic 
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Of the 11 palpable facial nodes, only one (9%) had metastatic involvement, while 
of the 13 palpable cervical nodes 5 were metastatic nodes (38%) (figure 15).  Palpable 
facial nodes did not necessarily indicate metastasis.  
Metastatic
1
9%
Metastatic
5
38%
0
2
4
6
8
10
12
14
Palpable Facial nodes
(N=11)
Palpable Cervical
nodes (N=13)
Fig 15.   Proportion of Palpable Facial and 
Cervical Lymph Nodes that are metastatic
 
 
Palpable  
 
8 
Metastatic 
 
5                 4 
Figure 14.  Proportion of palpable cervical nodes which were metastatic. 
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Only one of the three patients with metastatic facial node involvement had 
associated cervical lymph node metastasis.  
  Five patients in this group had no palpable cervical or facial lymph nodes.  Of 
these, only one had metastatic deposits on histopathological examination.  Clinically 
impalpable cervical and facial nodes may still have lymph nodal disease.   
Node Size 
The size of the facial node did not correspond to whether it harbored tumor or not.  
The median size of the positive facial node was 1.5 cm (1-2 cm) and the median size of a 
benign enlarged facial node was 1.05 cm (0.5-2.5). The p value was 0.353, (Mann-
Whitney U test), which was not significant.  The facial node was reported to have 
reactive hyperplasia in all of the enlarged nodes with no metastasis. 
Two of the patients with metastases in the facial node had the facial node as the 
only node involved. The primary tumours in this case were carcinoma of the lower 
alveolus and buccal mucosal carcinoma. 
Follow Up 
All patients with nodal involvement and positive tumour margins were advised 
post -operative radiotherapy. Four patients developed recurrences within the study period. 
Of these two had no evidence of cervical and facial nodal metastasis.  Of the other two, 
one each had facial and cervical nodal histologically proven metastasis. 
Of the 3 patients with metastatic involvement of the facial node – one died in the 
hospital due to malignant pleural effusion and one died at home due to unknown causes ( 
figure 16). One patient who had had microscopically involved inferior surgical margin 
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was advised to have radiation therapy but defaulted and developed local and nodal 
recurrence 4 months later.  Two patients who had cervical metastasis also died. On of the 
them had a metastatic facial node also. 
Facial node
(N=3)
Cervical
node (N=9)
Died
Total No.
3
9
2
66%
2
22.2%
0
3
6
9
Fig 16.        Mortartality among patients with 
Lymph node metastasis.
 
  
There were four patients with recurrence.  All four had local recurrence. One had facial 
metastasis and nodal recurrence.   
Fig 17.  Disease recurrence in patients with 
lymphnode metastasis.
  3
  Recurrences
33%
1
 recurrence
33%
9 positive
3
positive
0
3
6
9
Facial node (N=3) Cervical node(N=9)
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The probability of palpable cervical nodes harbouring metastasis. 
 
 
 
 Metastasis 
present 
Metastasis 
negative 
Total  
Palpable 5 8 13 
Not 
palpable 
4 8 12 
Total 9 16 25 
 
Table 1. 
Odds ratio = 1.25 {95% CI (0.18< OR>8.76 )} insignificant. 
Relative risk = 1.15 {95% CI ( 0.4<RR> 3.31)}insignificant. 
Fisher exact 1- tailed p- value = 0.5599677 
 
The odds  and relative risk appear to indicate a trend for a  palpable cervical node 
to harbour metastasis.  However, this trend was not significant statistically. 
 
The probability of  palpable facial nodes harbouring metastasis. 
 
 Metastasis 
present 
Metastasis 
neg 
Total  
Palpable 1 10 11 
Not 
palpable 
2 12 14 
Total 3 22 25 
 
Table 2. 
Odds ratio = 0.60 {95% CI ( 0.20<OR> 10.79)}insignificant. 
Relative risk = 0.64 {95% CI ( 0.70<RR> 6.14)}insignificant. 
Fisher exact 1-tailed p- value = 0.5934783 
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The odds and relative risk of a palpable facial node was less than one suggesting 
an inverse relationship; i.e., that a palpable facial node is less likely to harbour metastasis 
than a non-palpable one. However, this was not statistically significant. 
 
 
Discussion: 
 
 
In this study, there were more men than women (19 Vs 6).  This is in keeping 
with the rest of the studies that have shown similar ratios.  The increased prevalence of 
tobacco consumption amongst men could be one of the reasons for this.  
A majority of the patients presented with advanced malignancies.  About 60% 
patients presented with T3 and T4 lesions. About 64% of patients also had nodal 
involvement, amounting to 84% of patients presenting with stage 3 or 4 disease.  
Out of the 10 patients with carcinoma of the buccal mucosa, 2 (20%) had facial 
node metastasis. Out of 4 patients with carcinoma of the lower alveolus, one (25%) had 
facial node metastasis. If one were to assume that a probability of more than 20% occult 
disease in an N0 neck should be considered as grounds for an elective neck dissection, 
facial node metastasis in cancers of the buccal cavity and lower alveolus cannot be 
ignored.  In our study, patients with buccal carcinoma and carcinoma of the alveolus were 
more likely to harbour metastasis in the facial node than in malignancies of the tongue.  
However, these numbers are too small to make a conclusion. 
The Facial node as described in Sheehan et al. and the others drains the buccal mucosa 
and may be the first echelon node in the metastatic spread of the disease. Further they 
may be the only nodes involved in the patient as noted in this study – an observation 
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supported by Sheehan’s study. The dissection of the facial node is not routinely 
performed; infact, the upper limit of a radical neck dissection is generally given as the 
lower border of the mandible.31 
Given that the Facial node is an important draining and a first echelon node and 
its metastatic involvement in carcinomas of the oral cavity was reported to be about 
unexpectedly high, 24%, it is not known whether the inclusion of the facial node in a 
radical neck dissection specimen would alter the progression of the disease or affect 
recurrence and survival. Further studies are needed in this area to clarify this issue..  
In this study, the metastatic involvement of the facial node was 12%.  This does not 
support the unusually high incidence of facial node metastatic involvement as noted by 
Sheehan. However as the number of facial node sampled are only 25, a greater sample 
size would be required for a statistically significant value. 
 
In this study, though the facial node was palpable in 11 patients, only one (9%) 
was positive for metastasis.  On the other hand, out of the 3 facial nodes found to have 
tumor metastasis in them, only one (33%) was palpable.  This is in contrast with cervical 
lymph node involvement of the population studied.  About 55% of palpable cervical 
lymphadenopathy was found to have metastatic deposits in them. Hence we observe that 
the presence of a palpable facial node is more likely to indicate a reactive hyperplasia and  
not metastatic involvement, while a palpable cervical lymph node is more likely to be 
malignant.  
The 3 patients with metastases in the facial node had advanced carcinoma of the 
oral cavity.  This would suggest that the facial node may be involved generally in the 
 57 
setting of advanced disease as suggested by Sheehan. Of the three, only one of the nodes 
was palpable.   
A larger node is generally thought to be benign.  In this study, I did not find any 
difference between the sizes of a benign and malignant facial node, though there was a 
trend towards the metastatic node being larger than a benign node.   
Once again, though numbers are too small to make a definite conclusion, it appears that 
absence of palpable facial nodes does not preclude metastasis to this node.  More data is 
required before a definite conclusion is made that in all neck dissections, the facial node 
must be dissected out as well. 
  It is also observed that the patients with facial node metastasis had a poorer 
outcome. Two patients died shortly after the operation and one had nodal and regional 
recurrence. The latter had inferior margin involved microscopically and was suggested 
post operative radiotherapy which he defaulted.   This observation confounds the 
interpretation of the results. However, this observation is similar to that in Sheehan’s 
report. As the numbers of patients studied are few, more number of patients may be 
required to draw a conclusion of statistical significance. 
 
 
Relevance and implications of the results: 
Facial node metastases may occur as a result of the facial nodes being the first 
echelon of lymphatic drainage from a primary site involved with carcinoma, or as a result 
of disturbances to the normal pattern of lymphatic drainage by established cervical 
metastasis. Given that lymph node metastasis decreases survival and worsens prognosis 
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of the patient, adequate consideration must be placed on its treatment, as it may be the 
reason for the nodal recurrence.  This study reports an overall 12%  involvement of facial 
node in oral cancers, a 20-25% metastatic involvement of the facial nodes in buccal and 
lower alveolar carcinoma and a consistently poor prognosis when the node is involved.  
This warrants special attention to the treatment  of this entity.   
 A palpable facial node does not always indicate metastasis. This may be of 
significance in our current staging of the disease. Currently the facial node is not taken 
into account in the staging of oral malignancies. On the other hand, clinicians, not 
specifically looking for a facial node, are likely to club the facial node with a level I 
lymph node and thus staging the patient higher.  While our sample size is small, this 
distinction is important.  Subjecting all patients to neck dissections is likely to give a 
positive yield of a less than 10%. 
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Summary and conclusions: 
• The metastatic involvement of the facial node was 12% in patients with oral 
squamous cell carcinoma. 
• Palpable facial nodes were more likely to be benign. 
• The facial node may be a first echelon node in some buccal and lower alveolar 
squamous cell carcinomas and its involvement may be upto 20% in these sites. In 
the light of this, it is suggested that on these grounds, the facial node be routinely 
biopsied in the neck dissections for carcinoma of the buccal cavity and lower 
alveolus. 
• Metastasis to the facial node was associated with poor outcome and nodal 
recurrence. 
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Limitations: 
 
1. The study had a sample size of only 25 patients over 20 months; this made the 
numbers too small to make definite conclusions 
2. Facial node could not be identified in all the neck dissections performed during 
the period of the study.  This is perhaps due to the fact that there were several 
surgeons of different caliber performing these operations.  
3. The short period of the study does not permit a long follow up. Recurrences 
could occur later. 
4. The histopathological examination did not include a search for   micro-
metastasis.  It is therefore possible that some nodes may be erroneously reported 
to be free of tumour. 
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Annexure 1.  Intraoperative view of the  Facial node. (The white mop overlies the 
mandible.)   The clamp points to the facial node.. 
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serial no Hosp No date Name Diagnosis 
Facial 
node 
+/- 
Palpable 
facial 
node +/- 
Palpable 
cervical LN +/- 
Cervial LN 
metastasis 
+/- pre op chemo/rt 
1 595549c 30/03/2005 Jagabandhu Acharrya 
Carcinoma buccal mucosa left side T3 
N1 M0 1 1 0 0  
2 725168a 28/10/2005 Chacko PV Carcinoma tongue Right side T2N2 M0 0 0 1 1 surgery 2001 
3 667096c 17/09/2005 Chandramani Tiwari 
Carcinoma tongue Right side T2 N0 
M0 0 0 0 0  
4 717631c 11/02/005 Anup Dutta Carcinoma tongue Right side T2N1 Mo 0 0 1 0  
5 688651b 15/09/2004 Sathyaseelan Carcinoma tongue right side T4 N0 M0 0 0 0 0  
6 317395b 02/022005 Ramalingam 
Carcinoma right buccal mucosa T3 N1 
M0 0 0 1 0  
7 578662c 2/3/2005 Badar Ali 
Carcinoma right lower alveolus T2 N2 
Mo 0 0 0 1  
8 559245c 23/03/2005 Chinnammal 
Carcinoma right buccal mucosa T3 
N2b M0 0 0 1 1 Neoadj chemo 
9 588131c 30/03/2005 Upendra Prasad Srivatsav 
Carcinoma right buccal mucosa T4 N1 
M0 0 1 1 0 Neoadj chemo 
10 634506c 17/05/2005 Kanika Das Carcinoma tongue right side T2 N1 M0 0 0 1 1  
11 615981c 6/1/2005 Shail Mishra 
Carcinoma Left lower Alveolus T4 N1 
M0 0 1 0 0 Neoadj chemo 
12 634896c 15/06/2005 Kanthamma 
Carcinoma right buccal mucosa T2N1 
M0 0 1 1 0  
13 099398c 6/10/2005 Parthasarthy Carcinoma tongue left side T2 No Mo 0 1 0 0  
14 555545c 6/7/2005 Gopen Mech 
Carcinoma right lower alveolus T4 N1 
Mo 0 0 1 0 Neoadj chemo 
15 680090c 24/8/2005 Prasanth Ranjan Carcinoma tongue right side T1 M0 N0 0 0 0 0  
16 682368c 5/10/2005 Reeba Dey Carcinoma tongue left side T4 No Mo 0 1 0 1  
17 706799c 2/11/2005 Rajamma 
Carcinoma right lower alveolus T4 N2 
Mo 1 0 1 0  
18 723760c 7/11/2005 Gaya Prasad 
Carcinoma buccal mucosa left side T4 
N0 M0 0 1 1 0  
19 731550c 11/1/2006 Jayaprakash Singh 
Carcinoma buccal mucosa left side T4 
N0 M0 0 0 0 0 Neoadj chemo 
20 652989c 18/01/2006 Kandaswamy 
Carcinoma right buccal mucosa T4 No 
Mo 0 1 1 0  
21 747803c 8/2/2006 Mary Verghese Carcinoma tongue right side T4 N1 M0 0 0 1 1 Neoadj chemo 
22 773481c 16/03/2006 Anrudh Shaw 
Carcinoma right buccal mucosa T4 N2 
Mo 1 0 1 1  
23 769016c 30/03/2006 Vinodh Kumar Singh Carcinoma tongue left side T3 N1 Mo 0 1 0 1 Neoadj chemo 
24 847134C 7/7/2006 Sandeep Kumar Das Carcinoma tongue left side T2 N1 Mo 0 1 0 1  
25 796833c 3/6/2006 Ajith Mondal 
Carcinoma buccal mucosa right side 
T2N0M0 0 1 0 0  
Annexure  2a 
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serial 
no Name Node size recurrence remarks surgery done 
1 
Jagabandhu 
Acharrya 2 1 
inferior mucosal 
margin involved.  
Advised immediate 
RT but defaulted.  4 
months later had local 
and nodal recurrence Left Composite resection + MRND + Flap 
2 Chacko PV 1 0  Rt hemiglossectomy + MRND 3  + post op RT 
3 
Chandramani 
Tiwari 1 0  Rt WLE+MRND + RT 
4 Anup Dutta 1 1 
Rt submandibular 
region recurrence Rt WLE+MRND3 
5 Sathyaseelan 1 0  Subtotal glossectomy + MRND + post op RT 
6 Ramalingam 1 0  WLE + SOHD 
7 Badar Ali 1 0  Rt composite resection + RT 
8 Chinnammal 1 1 local recurrence LEFT COMPOSITE RESECTION AND PECTORALIS MAJOR FLAP  
9 
Upendra 
Prasad 
Srivatsav 2 0  WLE+SOHD +STSG 
10 Kanika Das 2 0  WLE+ MRND1 
11 Shail Mishra 1 0  Left Composite resection + RT 
12 Kanthamma 1 1 
ant, sup, inf margins 
involved, had local 
recurrence and then 
underwent RT 
composite resection WLE+STSG + RT  followed by RT composite resection 
13 Parthasarthy 2 0  WLE + MRND 
14 Gopen Mech 1 0  Hemimandibulectomy + RND +Fibular graft 
15 
Prasanth 
Ranjan 2 0  Rt composite resection  
16 Reeba Dey 1 IP DEATH IP DEATH 
COMPOSITE RESECTION OF THE LEFT SIDE ,MODIFIED RADICAL 
NECK  DISSECTION + PECTORALIS MAJOR FLAP 
RECONSTRUCTION 
17 Rajamma 1  DIED Right Composite resection with Pectoralis Major Flap 
18 Gaya Prasad 2 0  L composite resection + MRND + forearm flap + postop RT 
19 
Jayaprakash 
Singh 1   Composite resection + RT 
20 Kandaswamy 1 0  WLE +Rr RND + L radial free forearm flap 
21 Mary Verghese 1 0  
RIGHT COMPOSITE RESECTION + PECTORALIS MAJOR 
MYOCUTANEOUS FLAP 
22 Anrudh Shaw 2 IP DEATH IP DEATH 
Right composite resection with partial maxillectomy with Left Radial 
forearm free flap reconstruction 
23 
Vinodh Kumar 
Singh 3 0  Left composite resection +  RND + FLAP 
24 
Sandeep 
Kumar Das 1 0  WLE TONGUE + MRND III 
25 Ajith Mondal 2 0  WLE + SOND 
Annexure  2b 
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Annexure  3 
 
Proforma: 
 
 
Name of the patient: 
Hospital Number    : 
Age: 
Sex: 
Date: 
Diagnosis: 
Neoadjuvant chemo or Radiation: 
Previous surgery if any: 
Palpable facial node +/-: 
Palpable cervical nodes +/-: 
 
Operation done: 
 
Diameter of the facial node: 
Facial node metastasis +/-: 
Cervical node metastasis +/-: 
  
Post op Radiation or Chemotherapy: 
Recurrence or follow up: 
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